Skip to main content
. 2018 May 14;13(5):e0197415. doi: 10.1371/journal.pone.0197415

Fig 3.

Fig 3

Total leucocyte (a), CD4+ T cell (b), CD8+ T cell (c) and CD19+ B cell (d) peripheral blood counts for each individual from baseline up to the 36th month of follow-up during RTX treatment. Horizontal lines indicate median and IQR cell concentration at baseline (i.e. before first RTX infusion).